MEMPHIS, Tenn.–(BUSINESS WIRE)–The spirit of Memphis was on full display this weekend as tens of thousands…
Categoría: Business Wire
Categoría agregada por el Plugin WPeMatico
Rosen Law Firm Encourages Klarna Group plc Investors to Inquire About Securities Class Action Investigation – KLAR
NEW YORK–(BUSINESS WIRE)–Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of…
HYMPAVZI® (marstacimab) Reduced Bleeds by 93% Compared to On-Demand Treatment in Adults and Adolescents with Hemophilia A or B with Inhibitors
Findings from the Phase 3 study were presented at the 67th American Society of Hematology Annual…
Star Therapeutics Presents Interim Data from Phase 1/2 Multidose Study of VGA039 in Von Willebrand Disease, Demonstrating Substantial Bleed Reductions in All Patients, at ASH Annual Meeting
VGA039 is a once monthly, subcutaneously self-administered therapy for the treatment of bleeding disorders, starting with…
Kite’s Next-Generation Bicistronic CAR T-Cell Therapies Show Encouraging Phase 1 Results in Relapsed/Refractory B-Cell Lymphoma in New Data at ASH 2025
– Initial Results from Kite-753, Optimized with Novel Manufacturing Process That Preserves T-Cell Fitness, Show High…
Arcellx Announces New Positive Data for Its iMMagine-1 Study in Patients with Relapsed and/or Refractory Multiple Myeloma
— Anito-cel demonstrated 96% ORR and 74% CR/sCR at a median follow-up of 15.9 months; responses…
Kite Announces New Data for Pivotal iMMagine-1 Study at ASH 2025, Highlighting Anito-cel’s Opportunity in Relapsed or Refractory Multiple Myeloma
– 96% Overall Response Rate, 74% Stringent Complete Response/Complete Response, and 95% Minimal Residual Disease Negativity…
Worthington Steel Issues Statement Regarding Klöckner & Co SE
COLUMBUS, Ohio–(BUSINESS WIRE)–Worthington Steel, Inc. (NYSE: WS) today issued the following statement: We confirm that we…
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response,…
Orca Bio Presents New Clinical Data on Orca-T® in Older Patients Using Reduced Intensity Conditioning Plus New Analyses from the Precision-T Phase 3 Study at the 67th ASH Annual Meeting
Patients aged 60-75 treated with Orca-T and a reduced intensity conditioning regimen (RIC) experienced low incidence…